GridAI Technologies Corp. (GRDX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
GridAI Technologies Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $5 | $2.74 | -$2.26 | -45.2% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 21 | $98 | $57.75 | -$40.25 | -41.07% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 47,800 | $96,556 | $138,620 | $42,064 | 43.56% |
GridAI Technologies Corp. (GRDX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has GridAI Technologies Corp. ever had a stock split?
GridAI Technologies Corp. Profile
| Biotechnology Industry | Healthcare Sector | Jason David Sawyer CEO | NASDAQ (CM) Exchange | 33749P507 CUSIP |
| US Country | 2 Employees | - Last Dividend | 18 Aug 2025 Last Split | - IPO Date |
Overview
GridAI Technologies Corp. is a progressive clinical-stage biopharmaceutical company committed to the innovative research and development of targeted, non-systemic therapies aimed at addressing gastrointestinal diseases. Established on January 30, 2014, the company is based in Boca Raton, Florida, and focuses on creating specialized treatments that offer effective solutions for patients suffering from various gastrointestinal conditions. The company's dedication to advancing healthcare solutions is evident in its robust pipeline of therapeutic candidates.
Products and Services
- Latiglutenase
Latiglutenase is an innovative enzyme therapy designed to aid patients with gluten sensitivity. It works by breaking down gluten proteins in the digestive system, potentially alleviating symptoms associated with gluten ingestion in affected individuals.
- Capeserod
Capeserod is a drug in development targeting gastrointestinal motility disorders. It is designed to selectively act on the receptors involved in gastrointestinal movement, potentially providing relief from symptoms associated with conditions such as irritable bowel syndrome and chronic constipation.
- Adrulipase
Adrulipase is a novel enzyme replacement therapy aiming to treat patients with exocrine pancreatic insufficiency. This therapy enhances fat digestion and absorption, helping patients manage nutrient deficiencies and improve their overall quality of life.
- Niclosamide
Niclosamide is an anti-parasitic agent that is being repurposed for treating certain gastrointestinal conditions. The compound has previously shown efficacy against various pathogens and is under exploration for its potential benefits in treating gastrointestinal inflammatory diseases.
